Renovaro Biosciences Appoints Simon Tarsh as Interim CFO

An update from Renovaro Biosciences (RENB) is now available.

Renovaro Inc. has named Simon Tarsh as their Interim Chief Financial Officer, drawing on his extensive experience from Deloitte and his own consulting firm, Tarsh PB Advisors LLC. Recognized for his expertise in operational transformation and finance operations on a global scale, Tarsh brings valuable insights to the growing company. Under the consulting agreement, he will earn $25,000 monthly and potentially receive additional compensation, including stock options, for achieving certain milestones. His appointment comes as the previous CFO, Ms. Puche, steps down after five years to pursue a new life phase, yet remains supportive during the transition.

See more insights into RENB stock on TipRanks’ Stock Analysis page.